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Abstract
Background: Fc-glycosylation of monoclonal antibodies (mAbs) has profound implications on the Fc-mediated effector
functions. Alteration of this glycosylation may affect the efficiency of an antibody. However, difficulties in the production of
mAbs with homogeneous N-glycosylation profiles in sufficient amounts hamper investigations of the potential biological
impact of different glycan residues.
Methodology/Principal Findings: Here we set out to evaluate a transient plant viral based production system for the rapid
generation of different glycoforms of a monoclonal antibody. Ebola virus mAb h-13F6 was generated using magnICON
expression system in Nicotiana benthamiana, a plant species developed for commercial scale production of therapeutic
proteins. h-13F6 was co-expressed with a series of modified mammalian enzymes involved in the processing of complex N-
glycans. Using wild type (WT) plants and the glycosylation mutant DXTFT that synthesizes human like biantennary N-
glycans with terminal N-acetylglucosamine on each branch (GnGn structures) as expression hosts we demonstrate the
generation of h-13F6 complex N-glycans with (i) bisected structures, (ii) core a1,6 fucosylation and (iii) b1,4 galactosylated
oligosaccharides. In addition we emphasize the significance of precise sub Golgi localization of enzymes for engineering of
IgG Fc-glycosylation.
Conclusion: The method described here allows the efficient generation of a series of different human-like glycoforms at
large homogeneity of virtually any antibody within one week after cDNA delivery to plants. This accelerates follow up
functional studies and thus may contribute to study the biological role of N-glycan residues on Fcs and maximizing the
clinical efficacy of therapeutic antibodies.
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Introduction
Due to their outstanding specificities recombinant monoclonal
antibodies (mAbs) have become one of the most promising products
of the biopharmaceutical industry. Although the defining trait of an
antibody is its specificity for the target antigen, subsequent effector
functions, i.e. elimination of the antigen–antibody complex, are of
majorsignificance.Thesefunctionsaremediatedbytheinteractionof
IgG Fc-domain with gamma Fc receptors (FccRs) that are expressed
by various cells. Many studies have demonstrated the critical role of
the oligosaccharides attached at a single conserved site of the Fc
domain for the antibody’s effector functions [1,2]. Thus glycosylation
has been a focus of interest for the biopharmaceutical industry for the
past several years, and cell lines have been engineered in efforts to
optimize antibody products by the differential addition of fucose,
galactose, bisecting N-acetylglucosamine (GlcNAc) and sialic acid
[1,2]. However, duetothelarge endogeneous glycosylationrepertoire
of the most widely used mammalian production cell lines CHO,
NS0 and Sp2/0, it is currently difficult to generate mAbs with
homogeneous profiles, thus hampering the investigation of the
possible biological impact of specific N-glycan residues. Even the
isolation of a single glycoform of a well-known glycoprotein in order
to advance structure-function studies presents an enormous challenge
[3]. Thus, there is an increasing demand for expression platformsthat
allow the rapid and efficient generation of proteins with defined
homogeneous N-glycan patterns.
Recent achievements in production speed and yield of recom-
binant proteins has established plants as an attractive alternative
expression system to cell based platforms [4,5]. Notably, plant viral
based transient expression platforms, like magnICON, allow the
expression of large amounts of recombinant proteins within one
week after delivery of appropriate DNA constructs [4], thus offering
a new area in the field of pharmaceutical biotechnology [6]. One
potential drawback of using such expression vectors is the
reprogramming of the host proteome associated with the viral
replication [7,8]. These changes include alterations along the
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tions, like N-glycosylation, occur. Compared to other expression
platforms like yeast and bacteria, plants provide the advantage that
they synthesize mammalian type complex N-glycans. Efforts
towards humanization of plant glycosylation resulted in the
generation of mutants that synthesize human type glycans at great
uniformity [10–15]. Monoclonal antibodies produced in such
mutants can exhibit enhanced effector function activity
[10,11,16]. Recent advances in the development of transient
expression systems have placed N. benthamiana in a central position;
this plant species has been used at commercial scale for production
of therapeutic proteins (KBP, http://www.kbpllc.com/). In the
course of humanizing the plant glycosylation machinery a N.
benthamiana glycosylation mutant DXTFT was generated that
enables the generation of mAbs with virtually one single N-glycan
species, i.e. human like biantennary N-glycans with terminal N-
acetylglucosamine on each branch (GnGn structures) [13]. Such
GnGn oligosaccharides provide the key structure for further
elongation/modification steps, e.g. fucosylation, branching, galac-
tosylation and sialylation. Indeed, glyco-engineered DXTFT served
as host for the generation of recombinant proteins elongated with
b1,4 galactose, sialic acid and GlcNAc branched or bisected
residues [14,15,17], i.e. N-glycan species not naturally present in
plants but frequently observed on mammalian proteins. Although
these tests of concept studies demonstrate the potential of plants to
be used as a versatile expression system for the generation of
complex human therapeutic proteins with a customized N-glycan
profile,itisnotknown whetherthese achievements translate tolarge
scale manufacturing. Moreover, as different reporter proteins were
used in these studies, limited information about the feasibility to
manipulate IgG-Fc glycosylation is available.
In this study we set out to evaluate, in a systematic way, the
feasibility to engineer IgG Fc glycosylation upon high expression
in N. benthamiana WT and DXTFT. The magnICON system which
allows the expression of up to 4,8 mg mAb/gram leaf fresh weight
[6] was used to generate mAbs with a customized N-glycosylation
pattern avoiding time consuming transformation events. To this
end we transiently co-expressed various modified human glyco-
sylation enzymes (Figure 1) together with Ebola virus monoclonal
antibody (h-13F6) [18] cloned into the magnICON system. h-
13F6 was harvested at different time points and subsequently
subjected to N-glycosylation analyses by ESI-MS. We demonstrate
an efficient way to modify Fc glycosylation towards human glycan
structures that are relatively homogenous.
Results
Expression of h-13F6 in N. benthamiana WT and DXTFT
In this study we used the viral based magnICON system [4] for
high expression of the humanized Ebola virus antibody h-13F6
[18]. Appropriate magnICON vectors carrying cDNAs from h-
13F6 heavy and light chain in TMV and PVX respectively [19],
were agroinfiltrated into leaves of N. benthamiana WT and the
glycosylation mutant DXTFT [13]. Leaves were harvested at time
points with maximal expression levels, i.e. 5–8 days post-
infiltration (dpi). The expression levels were about 0.5 mg
assembled IgG/g leaf biomass as estimated by Sandwich ELISA.
This corresponds to about 10% of total soluble proteins. Infiltrated
leaves were homogenized and extracts subjected to Protein A
affinity based purification. SDS-PAGE analysis of purified h-13F6
exhibited two bands representing the heavy and the light chain,
with marginal or no degradation products (Figure 2). Subsequently
N-glycosylation analysis of h-13F6 was performed using liquid-
chromatography electrospray ionization-mass spectrometry (LC-
ESI-MS). The N-glycan profile of h-13F6 derived from N.
benthamiana WT (h-13F6WT) exhibited a largely homogeneous
GnGnXF
3 pattern with plant specific b 1,2 xylose and core a1,3
fucose residues (Figure 3). Some minor glycoforms representing
GnGn and GnGnX were present. h-13F6 derived from DXTFT
(h-13F6DXTFT) carried one single dominant N-glycan species, i.e.
Figure 1. Schematic presentation of reactions catalyzed by b1,4 galactosyltransferase (GalT), N-acetylglucosaminyltransferase III
(GnTIII) and core a1,6 fucosyltransferase (FUT8). GlcNAc: N-acetylglucosamine, UDP: Uridine diphosphate; GDP: guanosine diphosphate.
doi:10.1371/journal.pone.0026040.g001
Monoclonal Antibody Glycoforms
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26040GnGn structures (Figure 3). Both, h-13F6WT and h-13F6DXTFT,
exhibited only minor nonglycosylated fractions (5–10%). No
significant differences in the N-glycan pattern were obtained upon
harvesting at different time points (a range from 4–10 dpi was
monitored). The results are in accordance with results obtained by
expressing other mAbs at lower levels in the same plants [13,17],
demonstrating that high level expression of mAbs does not alter
the quality of the products in terms of proteolytic degradation and
Fc glycosylation. In addition the glycosylation profile of CHO
(ATCC collection: CHO-K1) derived h-13F6 (13F6CHO) was
determined and the spectrum revealed the presence of four main
glycan species, all of them core a1,6 fucosylated GnM F
6,
GnGnF
6, AGnF
6 and AAF
6.
In further experiments we aimed to modify the N-glycosylation
profile towards human like structures by the transient coexpression
of mammalian glycosyltransferases (GT) with h-13F6 in WT as
well as in DXTFT plants. Three GTs were used to generate a1,6
fucosylated, b1,4 galactosylated and bisected oligosaccharides
(FUT8, GalT, GnTIII, respectively). As the correct sub Golgi
localization of the enzymes has profound consequences for the
mode of modification, GTs with heterologous Golgi targeting
sequences were generated.
Generation of h-13F6 with core a1,6 fucosylated complex
N-glycans
The great majority of serum IgG and mammalian cell produced
mAbs carry complex N-glycans with core a1,6 fucose [20]. Though
in previous studies it was demonstrated that the elimination of this
sugar residue enhances Fc-mediated effector functions of many
mAbs [21] the role of this abundantly present N-glycan residue has
not yet been investigated in detail. Here we set out to replace the
plant specific core a1,3 fucosylation by the typical mammalian type
a1,6-linkage. Thus the respective human enzyme a1,6 fucosyl-
transferase(FUT8, Figure 1)wastransiently expressedinDXTFT, a
glycosylation mutant lacking plant specific xylose and importantly
core a1,3 fucose. Agrobacteria containing FUT8 cloned into a
binary vector (Figure S1) that enables low to moderate gene
expression in plants [13,17], were mixed with the magnICON
based vectors containing cDNAs of h-13F6. These mixtures,
containing 3 different agrobacteria strains, were infiltrated into N.
benthamiana DXTFT leaves and harvested at different time points,
starting with 4 dpi. As expression of h-13F6 reaches its maximum
level at 5–8 dpi and then drops, the latest harvesting point was 10
dpi. Purified 13F6 subjected to LC-ESI-MS analysis shows a
homogenous N-glycosylation profile with efficient core a1,6
fucosylation already at 4 dpi which remains stable until 10 dpi
(Figure 4 and data not shown). Virtually all GnGn structures were
converted to GnGnF
6.
Generation of h-13F6 with b1,4 galactosylated N-glycans
As in other higher eukaryotes GnGn is the required acceptor
substrate for further processing and elongation steps (Figure 1). In
a recent study we demonstrated the efficient elongation of this
structure by b1,4 galactose [17], an oligosaccharide structure
frequently observed in human serum IgG and on recombinant
therapeutic antibodies [2,20], however not naturally synthesized in
plants. This was achieved by the stable over-expression of a
modified version of the human b1,4 galactosyltransferase (
STGalT)
targeted to a late Golgi compartment where the final steps of
glycosylation take place [17]. The catalytic domain of the enzyme
was fused to the cytoplasmic-transmembrane-stem (CTS) domain
of rat a2,6 sialyltransferase (ST), a potent late Golgi targeting
sequence. However, the generation of such plants is time
consuming and needs advanced plant transformation/regenera-
tion knowledge which may limit their widespread use. In this study
we set out to obtain efficient IgG galactosylation by the transient
co-expression of the respective human enzyme in DXTFT
(Figure 1).
STGalT cloned into a binary vector (Figure S1) was
mixed with h-13F6 constructs and coinfiltrated in DXTFT plants.
Infiltrated leaves were harvested at different time points and
purified mAb was subjected to N-glycosylation analyses. N-glycan
profiles exhibited already at 4 dpi high fractions of galactosylated
N-glycans. Biantennary N-glycans with terminal galactose on each
branch (AA structures) were the major N-glycan species (Figure 5).
Importantly Fc galactosylation stays consistent irrespective of the
harvesting date (6 dpi and 8 dpi; Figure 5). In addition, no
modified GnGn structures, monogalactosylated AGn and incom-
pletely processed MA structures were present (Figure 5). h-13F6
harvested 10 dpi carried only minor amounts of galactosylated N-
glycans (less than 5%). At this time point the major N-glycan
species are non modified GnGn oligosaccharides (Figure S2). As a
next step we wanted to determine whether
STGalT and FUT8 can
act in a synchronized way to generate galactosylated and core a1,6
fucosylated structures. Upon coexpression of both enzymes with h-
13F6 in DXTFT GnGn structures were efficiently converted to
AAF
6 structures (Figure 5). Consistent with the results described
above, galactosylation decreases 10 dpi, while fucosylation remains
stable at that time point (data not shown). A surprisingly high
proportion of nonfucosylated GnGn structures are present, which
is in contrast to the efficient fucosylation of GnGn structures upon
expression of FUT8 alone (Figure 4). It seems that the
coexpression of FUT8 with
STGalT inhibits the addition of a1,6
fucose to GnGn structures.
Generation of h-13F6 with complex bisected N-glycans
An additional glycoform frequently observed in human serum
IgG but absent in mAbs expressed recombinantly in CHO cells, is
bisecting N-acetylglucosamine [20]. To date no specific contribu-
tion to mAb or IgG activities have been assigned to these
oligocaccharide structures, due in part to the difficulty to generate
Figure 2. Commassie blue stained SDS-PAGE of Protein A
purified h-13F6 glycoforms. Lane 1–4: h-13F6WT, h-13F6DXTFT,
h-13F6DXTFT +FUT8, h-13F6WT+
STGnTIII. M, molecular weight marker
(in kDa).
doi:10.1371/journal.pone.0026040.g002
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26040Figure 3. N-Glycan profiles of h-13F6 expressed in different hosts. N-glycan analysis was carried out by liquid-chromatography-electrospray
ionization-mass spectrometry (LC-ESI-MS) of tryptic glycopeptides as described previously [13;20]. Note, that during this procedure two
glycopeptides are generated that differ in 482 Da. Glycopeptide 1 is indicated with asterisks carry (*). See http://www.proglycan.com for N-glycan
abbreviations. h-13F6WT, h-13F6DXTFT: h-13F6 generated in WT and in DXTFT N. benthamiana, respectively; h-13F6CHO: h-13F6 produced in CHO cells.
doi:10.1371/journal.pone.0026040.g003
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oligosaccharides by over-expressing human N-acetylglucosamine-
transferase III (GnTIII), the enzyme that adds GlcNAc to mannose
in b1,4-linkage (Figure 1). Since it was shown previously that the
native human enzyme expressed in tobacco generates large portions
of bisecting GlcNAc, but with incompletely processed hybrid
structures [22], we hypothesized that its activity interferes with the
endogeneous plant N-glycosylation machinery. Indeed, a construct
that targets the enzyme to a late stage in the glycosylation pathway,
byfusingthecatalyticdomainofGnTIIItotheCTSregionoftherat
a2,6 sialyltransferase facilitate the generation of fully processed
bisecting N-glycans on erythropoietin expressed in plants [15]. This
STGnTIII binary construct (Figure S1) was used for h-13F6
coinfiltrationexperimentsinDXTFT.Surprisinglyh-13F6produced
in this way carried unprocessed GnGn structures, only minor
amounts of GnGnbi structures were detected (Figure 6). In con-
trast, using WT plants as expression hosts, a significant portion of
bisecting structures (GnGnXF
3bi) were generated. The quantity of
GnGnXF
3bi remains stable form 4–10 dpi (data not shown). An
interesting observation was made by fusing GnTIII to a targeting
sequence that directs the enzyme to a medial Golgi compartment
(i.e. CTS of core a1,3 fucosyltransferase; FUT11, Figure S1). Co-
expression ofthismodified enzyme (
FUT11GnTIII) [15]inWTplants
resulted in the generation of h-13F6 with a significant reduction of
plant specific N-glycan residues, which was particularly pronounced
for core a1,3 fucosylation; the three major glycoforms were GnGn
and GnGnX and GnGnXF
3 (Figure S3). Coexpression of h-13F6
with both
FUT11GnTIII and
STGalT resulted in efficient generation
of galactosylated GnGn and GnGnX structures (i.e. AAX and AA
structures, Figure 6). Interestingly, no fucosylated structures were
detected indicating a severe interference of the mammalian enzymes
with the endogeneous glycosylation machinery.
Discussion
The magnICON based expression system used in this study
yielded reliable, uniform and high-level expression of h-13F6, a
mAb being developed as a therapeutic product against Ebola virus
infection [18,19]. Here we demonstrate an efficient and rapid way
to modify mAb Fc-glycosylation towards homogeneous human-
Figure 4. N-Glycan profiles of h-13F6DXTFT coexpressed with human a1,6 fucosyltransferase (FUT8) and harvested at 4 and 8 dpi.
doi:10.1371/journal.pone.0026040.g004
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generated within one week after cDNA delivery to plants. Fcs that
carry quantitative amounts of b1,4 galactosylated, a1,6 fucosylated
and bisecting oligosaccharides were produced. These glycoforms
are abundantly present in serum IgG, but are difficult to generate
individually, if at all, in established mammalian cell based
expression platforms. Expression levels of all h-13F6 glycoforms
were comparable with levels of about 0.5 mg assembled IgG/g
leaf material. This corresponds to about 10% of total soluble
protein (TSP). Previously we reported the generation of glycoen-
gineered mAbs in the range of 0,2% of TSPs using binary vectors
[13,17]. This high expression of h-13F6 with a targeted Fc
glycosylation pattern is remarkable, since it requires the synchro-
nization of two expression systems that work in different ways.
While h-13F6 is produced by viral based replicons, the
glycosylation enzymes are generated by non replicating binary
vectors. Our results demonstrate that viral based expression which
is accompanied by a massive alteration of the entire host cell
machinery does neither negatively interfere with the binary
expression system nor with intracellular mechanisms facilitating
efficient secretion of recombinant proteins. Efficient complex
N-glycosylation, the low amount of non-glycosylated h-13F6
(5–10%) and the correct sub Golgi localization of mammalian
glycosyltransferases within the Golgi compartments indicate that
the secretory pathway of N. benthamiana is fully intact despite its
massive overload of cargo protein. These results corroborate
observations made with other viral based expression systems using
elements from cow pea mosaic virus [23]. h-13F6 seems to be
particularly stable as frequently degradation products of plant
produced mAbs are observed [23,24].
Due to the conformational complexity of IgG, Fc N-glycans are
to some extent buried at the protein backbone which hinders
optimal accessibility to N-glycan processing enzymes [25]. In this
light efficient modification of h-13F6 oligosaccharides is amazing.
Notably, a particularly highly homogeneous N-glycan profile was
obtained upon infiltration of DXTFT with FUT8; h-13F6 Fc
consisted of virtually one single N-glycan species, i.e. GnGnF
6.
Such homogeneity cannot be achieved by any mammalian based
expression system and has not been reported by any other cell
based expression system such as glycoengineered yeast [26]. Also,
efficient galactosylation of h-13F6 was achieved by the transient
co-expression of
STGalT. Over 60% of the obtained structures
Figure 5. N-Glycan profiles of h-13F6DXTFT coexpressed with (top) human b1,4 galactosyltransferase fused to the CTS of rat a2,6
sialyltransferase (
STGalT) and with (bottom) both
STGalT and FUT8, harvested at 6 dpi.
doi:10.1371/journal.pone.0026040.g005
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PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26040Figure 6. N-Glycan profiles of (top) h-13F6DXTFT and (middle) h-13F6WT coexpressed with human N-acetylglucosaminetransferase III
fused to the CTS of rat a2,6 sialyltransferase (
STGnTIII). (bottom) N-Glycan profile of h-13F6WT coexpressed with both
STGalT and human N-
acetylglucosaminetransferase III fused to the CTS of Arabidopsis thaliana core a1,3 fucosyltransferase (
FUT11GnTIII), harvested at 6 dpi.
doi:10.1371/journal.pone.0026040.g006
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coexpression of FUT8 with
STGalT slightly inhibits the addition of
a1,6 fucose to GnGn structures as a significant portion of h-13F6
consists of unprocessed GnGn structures. Surprisingly, h-13F6 Fc
N-glycans were only marginally processed upon
STGnTIII
expression in DXTFT. On the other hand bisecting GlcNAc
structures were efficiently synthesized using WT plants as
expression hosts indicating the requirement of additional core N-
glycan residues (in our case fucose and/or xylose) for the
generation of this structure. These results are in line with those
obtained recently in our laboratory by the co-expression of an
erythropoietin (EPO)-Fc fusion with
STGnTIII in DXTFT. While
EPO exhibited large fractions of GnGnbi structures, only marginal
amounts of bisecting structures (less than 5%) were detected on the
Fc portion [15]. The results point to the importance of the protein
backbone in the generation of certain glycosylation profiles and
corroborate non-optimal accessibility of Fc N-glycans for some N-
glycan processing enzymes. For the readers’ convenience we
have listed publications derived from our laboratory in
Table S1.
While FUT8 and
STGnTIII still convert respective substrates
very efficiently to GnGnF
6 and GnGnXFbi even up to 10 dpi, only
minor amounts of galactosylated structures were detected at that
time point upon
STGalT expression. Using binary vectors, a
decrease of expression of the respective proteins is expected 5–6
dpi, thus the presence of highly active
STGnTIII and FUT8 10 dpi
came as a surprise. It seems that fucosylation and the transfer of
bisecting GlcNAc needs less enzymatic activity than galactosyla-
tion. These results are in agreement with the predominance of
a1,6 fucosylated in serum IgG [20].
We demonstrate the importance of correct targeting of gly-
cosylation enzymes within the Golgi compartments. Although upon
expressing GnTIII and GalT in tobacco substantial fraction of
bisecting GlcNAc and galactosylated structures were generated,
large portions of unusual and incompletely processed structures
were present [22,27] indicating an interference of these enzymes
with plant endogeneous glycosylation enzymes. A similar observa-
tion was made in CHO cells upon over-expression of GnTIII
[21,28]. These obscure structures were completely absent when the
enzyme was targeted to a late stage of the glycosylation pathway as
observed previously and in this study by the use of ST-CTS
targeting signals [15,17]. As shown for other proteins, CTS of rat
a2,6 sialyltransferase seems to be a very potent late Golgi targeting
sequence inplantsthus targetingthehuman enzymesto a final stage
of the glycosylation pathway. This allows endogeneous N-glycan
processing to complete prior transfer of the bisecting GlcNAc
residue and galactosylation. Another interesting observation is the
generationoflarge fractions ofGnGnand GnGnX structures,along
with a significant reduction of core fucosylated structures by the co-
expression of h-13F6 with
FUT11GnTIII in N. benthamiana WT. This
reduction of fucose (and xylose) is not observed when GnTIII is
targeted to a late Golgi compartment by using ST-CTS as targeting
sequence. The CTS region of FUT11 targets proteins potentially to
early/medial Golgi compartments. In addition, only low levels of
bisecting N-glycans (less than 5%) were generated. It seems that the
three enzymes,
FUT11GnTIII endogeneous core a1,3 FucT and
XylT inhibit each other when they act in close proximity. This
currently not entirely inexplicable inhibition is more pronounced
for FucT. Remarkably GnGn and GnGnX structures are efficiently
converted to galactosylated AA and AAX structures upon
coexpression of
FUT11GnTIII and
STGalT. Moreover, upon
coexpression of these enzymes a complete inhibition of endoge-
neous fucosylation is obtained, indicating a severe interference of
the mammalian enzymes with the endogeneous glycosylation
machinery, as a consequence of intra Golgi localization. These
results confirm high coordination of the glycosylation enzymes
within the Golgi compartments, and point to the tremendous
importance of precise targeting of the glycosylation enzymes in
engineering N-glycan profiles.
The in vivo production of specific human-like glycoforms is in its
infancy and access to truly homogeneous glycoproteins remains
limited. Despite the technical hurdles associated with the
introduction of human-type glycosylation machinery into a foreign
organism, our results indicate that plants have the potential to
offer a significant alternative to mammalian cell culture as a source
of humanized glycoproteins. The clinical success of monoclonal
antibodies has been demonstrated by a number of antibody
therapeutics. Nevertheless, it is still very important to optimize
their clinical efficacy. Clinical trials using therapeutic antibodies
fully lacking core fucose residues in the Fc oligosaccharides are
currently underway, and their remarkable physiological activities
in vivo have attracted attention as next-generation therapeutic
antibody approaches with improved efficacy [29,30]. However,
the biological impact of other major glycoforms present in serum
IgG is largely unknown. The rapid generation of different
glycoforms of virtually any mAb as described here will advance
functional studies and thus significantly contributes to optimize the
clinical efficacy of therapeutic antibodies.
Materials and Methods
Plant expression binary vectors
Binary vectors used in this investigation for the expression
of mammalian glycosyltransferases in plants were previously
described:
STGalT [17];
FUT11GnTIII and
STGnTIII [15].
Schematic presentation of all constructs, including FUT8, is
shown in Figure S1. Generation of magnICON vectors carrying
the cDNA of h-13F6 heavy and light chains is described elsewhere
[19].
h-13F6 infiltration and purification
Nicotiana benthamiana WT and DXT/FT plants [13] were grown
in a growth chamber at 22uC with a16 h light/ 8 h dark
photoperiod. Leaves of four to five week old plants were used for
agroinfiltration experiments. Agrobacteria transformed with the
TMV and PVX based-vectors containing the h-13F6 cDNA for
the heavy and light chains were grown at 29uC for 24 hours. After
harvesting by gentle centrifugation (5 min at 3000 g), the bacteria
were ressuspended in buffer (10 mM MES pH 5.6; 10 mM
MgSO4), mixed and diluted to a final OD600 of approximately
0.1–0.2. In experiments aimed to modulate plant glycosylation,
agrobacteria transformed with binary vectors containing the
cDNA of specific mammalian glycosyltransferases were prepared
the same way and included in the infiltration mixture to be co-
infiltrated with the viral-based vectors.
Approximately 200–250 mg of infiltrated leaf material was
homogenized, mixed with 600 mL extraction buffer (500 mM
NaCl; 100 mM Tris/HCl; 40 mM L(+) ascorbic acid; 1 mM
EDTA; pH=6,8) and incubated on ice for 10 min. After
centrifugation (3615 min at 9.600 g) supernatant was incubated
with 15–20 mL ProteinA Sepharose
TM Fast Flow (GE Healthcare)
for 1 h30 min at 4uC. After a brief spin down, the supernatant was
discarded and the Sepharose was washed 3 times with 1x PBS
using Micro Bio-Spin chromatography columns (Bio-Rad). 30 mL
of 100 mM Glycine/HCl pH=2.5 were applied to the column
and the eluate containing the purified IgG was neutralized by
adding 1.2 mL of 0.5 M Tris.
Monoclonal Antibody Glycoforms
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N-glycan analyses were carried out by liquid-chromatography
electrospray ionization-mass spectrometry (LC-ESI-MS) of tryptic
glycopeptides as recently described [20]. Briefly, the heavy chain
band of purified, SDS-PAGE separated IgGs was cut from the gel,
S-alkylated, digested with trypsin, eluted from the gel fragment
with 50% acetonitril and separated on a Biobasic C18 column
(15060.32 mm, Thermo Electron) with a gradient of 1–80%
acetonitrile containing 65 mM ammonium formate pH 3.0.
Positive ions were detected with a Q-TOF Ultima Global mass
spectrometer (Waters, Milford, MA, USA). Summed and
deconvoluted spectra of the glycopeptides elution range were
used for identification of glycoforms. This method generates two
glycopeptides that differ by 482 kDa (glycopeptide 1, EEQFN-
STYR; glycopeptide 2 TKPREEQFNSTYR). Please note that the
original h-13F6 produced in CHO (CHO-K1 ATCCH Catalog
No. CCL-61) generates two glycopeptides that differ, compared to
the plant produced version, in one amino acid: (glycopeptide 1,
EEQYNSTYR; glycopeptide 2 TKPREEQYNSTYR). This
change results in a mass shift of 16 Da between the two versions
in LC-ESI-MS analyses. The transfer of fucose in a1,6 linkage was
further investigated by PNGaseF digestion of an Fc fragment
(Figure S4) that was coexpressed with FUT8. PNGaseF is a well
known endoglycosidase that digests N-linked oligosaccharide,
except those carrying fucose in a1,3 linkage [31]. Complete
deglycosylation of the glycopeptides, including the assigned
GnGnF peak, further confirms a1,6 linkage of fucose.
Supporting Information
Figure S1 Schematic representation of the different
binary expression vectors used in this study.
STGalT:
cytoplasmic tail-transmembrane-stem region CTS of rat a2,6-
sialyltransferase (ST) fused to the catalytic domain of human b1,4-
galactosyltransferase. FUT8: human core a1,6-fucosyltransferase
full length;
STGnTIII: ST-CTS region fused to catalytic domain
of human b1,4-mannosyl-b1,4-N-acetylglucosaminyltransferase
(GnTIII);
FUT11GnTIII: CTS of A. thaliana core a1,3-fucosyl-
transferase fused to catalytic domain of GnTIII. Pnos: nopaline
synthase gene promoter; Tnos: nopaline synthase gene terminator;
P35S: promoter of the 35S transcript of the Cauliflower Mosaic
Virus; g7T: Agrobacterium gene 7 terminator; KanR: neomycin
phosphotransferase II; LB: left border; RB: right border.
(TIF)
Figure S2 N-Glycan profiles of h-13F6DXTFT coexpressed
with human b1,4 galactosyltransferase fused to the CTS
of rat a2,6 sialyltransferase (
STGalT) harvested 10 dpi.
(TIF)
Figure S3 N-glycosylation profile of h-13F6 expressed in
N. benthamiana WT together with
FUT11GnTIII.
(TIF)
Figure S4 Determination of a1,6 linkage of fucose on Fc.
N-glycosylation profile of Fc coexpressed with FUT8 (A),
and subsequent PNGaseF treatment (B). While several, and
particularly fucosylated GnGn glycoforms were present in A, upon
PNGaseF only de- and nonglycosylated peptides were detected in
B. The digestion of virtually all oligosaccharides including GnGnF
further confirms a1,6 linkage of this N-glycans residue.
(TIF)
Table S1 For convenience of readers a list of previous
own publication is provided.
(DOC)
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